Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02665650
Title Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Affimed GmbH
Indications

Hodgkin's lymphoma

Therapies

AFM13 + Pembrolizumab

Age Groups: adult
Covered Countries USA | ESP


No variant requirements are available.